Katarina Uttervall

503 total citations
25 papers, 229 citations indexed

About

Katarina Uttervall is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Katarina Uttervall has authored 25 papers receiving a total of 229 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 14 papers in Molecular Biology and 12 papers in Oncology. Recurrent topics in Katarina Uttervall's work include Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (10 papers) and Peptidase Inhibition and Analysis (6 papers). Katarina Uttervall is often cited by papers focused on Multiple Myeloma Research and Treatments (24 papers), Protein Degradation and Inhibitors (10 papers) and Peptidase Inhibition and Analysis (6 papers). Katarina Uttervall collaborates with scholars based in Sweden, United States and France. Katarina Uttervall's co-authors include Hareth Nahi, Evren Alici, Gösta Gahrton, Johan Lund, Johan Liwing, J Aschan, Adil Doganay Duru, Erik Holmberg, Markus Hansson and Gunnar Juliusson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Katarina Uttervall

24 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katarina Uttervall Sweden	8	202	122	121	31	28	25	229
Katia Mancuso Italy	8	240 1.2×	162 1.3×	154 1.3×	25 0.8×	23 0.8×	39	281
Serena Rocchi Italy	9	255 1.3×	180 1.5×	157 1.3×	33 1.1×	18 0.6×	31	301
Robin Carson United States	10	204 1.0×	138 1.1×	160 1.3×	36 1.2×	28 1.0×	33	258
Miguel Teodoro Hernández‐Garcia Spain	6	328 1.6×	264 2.2×	168 1.4×	39 1.3×	16 0.6×	10	373
Holly Lee Canada	9	100 0.5×	99 0.8×	94 0.8×	15 0.5×	35 1.3×	37	187
María-Victoria Mateos Spain	6	234 1.2×	177 1.5×	161 1.3×	38 1.2×	9 0.3×	13	281
Xenofon Papanikolaou United States	7	241 1.2×	167 1.4×	150 1.2×	50 1.6×	8 0.3×	30	310
Jane Estell Australia	7	171 0.8×	130 1.1×	120 1.0×	27 0.9×	27 1.0×	16	210
Louis Williams United States	9	110 0.5×	84 0.7×	67 0.6×	22 0.7×	10 0.4×	44	185
Todd Milliron United States	5	157 0.8×	82 0.7×	175 1.4×	18 0.6×	20 0.7×	8	253

Countries citing papers authored by Katarina Uttervall

Since Specialization

Citations

This map shows the geographic impact of Katarina Uttervall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katarina Uttervall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katarina Uttervall more than expected).

Fields of papers citing papers by Katarina Uttervall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katarina Uttervall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katarina Uttervall. The network helps show where Katarina Uttervall may publish in the future.

Co-authorship network of co-authors of Katarina Uttervall

This figure shows the co-authorship network connecting the top 25 collaborators of Katarina Uttervall. A scholar is included among the top collaborators of Katarina Uttervall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katarina Uttervall. Katarina Uttervall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Uttervall, Katarina, et al.. (2024). Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden. Cancer Medicine. 13(8). e7048–e7048. 5 indexed citations

Garfall, Alfred L., Lotfi Benboubker, Katarina Uttervall, et al.. (2024). MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 24. S549–S549. 1 indexed citations

Matous, Jeffrey, Albert Oriol, Alfred L. Garfall, et al.. (2024). Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial. Blood. 144(Supplement 1). 4749–4749.

Chari, Ajai, Lionel Karlin, Amrita Krishnan, et al.. (2024). Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study. Blood. 144(Supplement 1). 4734–4734. 1 indexed citations

Nahi, Hareth, Katarina Uttervall, Sandra Lockmer, et al.. (2023). Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma. Cancer Medicine. 12(22). 20736–20744. 2 indexed citations

Donk, Niels W.C.J. van de, Alfred L. Garfall, Lotfi Benboubker, et al.. (2023). Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.. Journal of Clinical Oncology. 41(16_suppl). 8033–8033. 16 indexed citations

Chaireti, Roza, Katarina Uttervall, Johan Lund, et al.. (2022). Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care. European Journal Of Haematology. 109(6). 749–754. 3 indexed citations

Lonial, Sagar, Sebastian Grosicki, Marek Hus, et al.. (2022). Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. Journal of Clinical Oncology. 40(16_suppl). 8019–8019. 17 indexed citations

Susek, Katharina H., Katarina Uttervall, Arnika Kathleen Wagner, et al.. (2021). Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups. European Journal Of Haematology. 106(4). 546–554. 2 indexed citations

10.

Callander, Natalie S., Vincent Ribrag, Paul G. Richardson, et al.. (2021). DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 138(Supplement 1). 897–897. 11 indexed citations

11.

Nahi, Hareth, Muhammad Kashif, Monika Klimkowska, et al.. (2021). Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). American Journal of Hematology. 96(8). 925–933. 10 indexed citations

12.

Uttervall, Katarina, et al.. (2019). Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?. European Journal Of Haematology. 103(6). 588–596. 22 indexed citations

13.

Uttervall, Katarina, Göran Wålinder, Robert Månsson, et al.. (2019). Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European Journal Of Haematology. 103(3). 247–254. 7 indexed citations

14.

Nahi, Hareth, Anna Genell, Göran Wålinder, et al.. (2017). Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population‐based data from the Swedish Myeloma Register. European Journal Of Haematology. 99(3). 216–222. 38 indexed citations

15.

Duru, Adil Doganay, Tolga Sütlü, Katarina Uttervall, et al.. (2015). Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. PLoS ONE. 10(9). e0138248–e0138248. 6 indexed citations

16.

Uttervall, Katarina, Adil Doganay Duru, Johan Lund, et al.. (2014). The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE. 9(7). e101819–e101819. 42 indexed citations

17.

Lund, Johan, Katarina Uttervall, Johan Liwing, et al.. (2013). Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients. European Journal Of Haematology. 92(1). 19–25. 4 indexed citations

18.

Uttervall, Katarina, Evren Alici, Johan Lund, et al.. (2013). A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis. Acta Haematologica. 130(1). 7–15. 4 indexed citations

19.

Uttervall, Katarina, Johan O. L. Andreasson, Johan Liwing, et al.. (2012). Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients. Blood. 120(21). 5033–5033. 2 indexed citations

20.

Ungerstedt, Johanna, Emma Watz, Katarina Uttervall, et al.. (2011). Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Medical Oncology. 29(3). 2191–2199. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact